edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Trial Timeline
Oct 1, 2009 → Apr 1, 2013
NCT ID
NCT00986154About edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin is a phase 3 stage product being developed by Daiichi Sankyo for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00986154. Target conditions include Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986154 | Phase 3 | Completed |
Competing Products
20 competing products in Venous Thromboembolism